The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can predict benefit from either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense scheduled doxorubicin and cyclophosphamide (ddAC). Patients with a pT1-3, pN0-3 tumor were randomized 1:1 between ddAC and TAC. The primary endpoint was a gene profile-treatment interaction for recurrence-free survival (RFS). We observed 117 RFS events in 664 patients with a median follow-up of 7 years. Hallmark gene set analyses showed significant association between enrichment in immune-related gene expression and favorable outcome after TAC in hormone receptor-negative, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) (triple-negative breast cancer [TNBC]). We validated this association in TNBC patients treated with TAC on H&E slides; stromal tumor-infiltrating lymphocytes (sTILs) ≥20% was associated with longer RFS (hazard ratio 0.18,  = 0.01), while in patients treated with ddAC no difference in RFS was seen (hazard ratio 0.92,  = 0.86,  = 0.02).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11357803PMC
http://dx.doi.org/10.1016/j.isci.2024.110425DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
gene expression
12
expression profile
8
doxorubicin cyclophosphamide
8
patients treated
8
rfs hazard
8
hazard ratio
8
predictive gene
4
profile adjuvant
4
adjuvant taxane
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!